Comparable stake leader
Anson Funds Management LP
SEC ownership of ONCOLYTICS BIOTECH INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001129928.
Disclosed value leader
Anson Funds Management LP
Comparable rows
2/50
Latest evidence
30 Jun 2026
- Public ticker
- ONCY on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Anson Funds Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Anson Funds Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001129928
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ONCOLYTICS BIOTECH INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Anson Funds Management LP
Disclosed value leader
Anson Funds Management LP
Comparable rows
2/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 7%
48 rows are not safely comparable across share classes.
13D/G row: Anson Funds Management LP
Showing 1-8 of 50 holder rows.
Quick read
Anson Funds Management LP leads the comparable SEC ownership view at 7%.
2 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Anson Funds Management LP's linked filing trail.
Comparable ownership
Top 2
Anson Funds Management LP
7%
Y-Intercept (Hong Kong) Ltd
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Anson Funds Management LP |
13D/G
|
7%
|
$10,708,670
7,649,050 shares
|
-$751,370 | 30 Sep 2025 |
| Y-Intercept (Hong Kong) Ltd |
13F
Company
|
0.01%
|
$12,624
13,290 shares
|
— | 30 Jun 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
—
class O/S missing
|
$708,082
745,350 shares
|
— | 30 Jun 2026 |
| Bernd R. Seizinger |
3/4/5
Director
|
—
mixed-class rows
|
$480,014
596,991 shares
mixed-class rows
|
+$187,224 | 01 Jun 2026 |
| Wayne Pisano |
3/4/5
Director
|
—
mixed-class rows
|
$415,892
522,414 shares
mixed-class rows
|
+$25,338 | 01 Jun 2026 |
| XTX Topco Ltd |
13F
Company
|
—
class O/S missing
|
$247,832
260,903 shares
|
— | 30 Jun 2026 |
| SEEDS INVESTOR LLC |
13F
Company
|
—
class O/S missing
|
$245,365
258,306 shares
|
— | 30 Jun 2026 |
| Kirk Look |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$242,087
547,515 shares
mixed-class rows
|
+$10,104 | 01 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$362,615.
Buys
$362,615
Insiders: 10
Sells
$0
Insiders: 0
Net
+$362,615
Shares: +404,282
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 404,282
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 404,282 | 0 | $362,615 | $0 | +$362,615 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to ONCOLYTICS BIOTECH INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Bernd R. Seizinger
Net 12M change
+$362,616
Latest report
01 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bernd R. Seizinger | Director | $480,014 | +$187,224 | +64% | Filing P/S | 01 Jun 2026 |
| Wayne Pisano | Director | $415,892 | +$25,338 | +6.5% | Filing P/S | 01 Jun 2026 |
| Kirk Look | Chief Financial Officer | $242,087 | +$10,104 | +4.4% | Filing P/S | 01 Jun 2026 |
| Thomas Charles Heineman | Chief Medical Officer | $233,890 | +$10,033 | +4.5% | Filing P/S | 01 Jun 2026 |
| Angela Holtham | Director | $190,984 | Mixed | 01 Jun 2026 | ||
| Jared Kelly | Chief Executive Officer, Director | $109,488 | +$34,369 | +46% | Filing P/S | 01 Jun 2026 |
| Allison Hagerman | Chief Technology Officer | $95,475 | +$8,298 | +9.5% | Filing P/S | 01 Jun 2026 |
| Deborah Margaret Brown | Director | $93,329 | +$21,240 | +29% | Filing P/S | 01 Jun 2026 |
| Patricia S. Andrews | Director | $66,854 | +$30,292 | +83% | Filing P/S | 01 Jun 2026 |
| Andrew Aromando | Chief Business Officer | $47,314 | +$25,418 | +116% | Filing P/S | 01 Jun 2026 |
| Jonathan Rigby | Director | $44,437 | Mixed | 01 Jun 2026 | ||
| Parsons James T. | Director | $43,104 | +$10,300 | +31% | Filing P/S | 01 Jun 2026 |
| John Bearden McAdory | Chief Operating Officer | Mixed | 01 Jun 2026 | |||
| Stephen C. Glover | Director | Mixed | 01 Jun 2026 |
Recent insider transactions for ONCOLYTICS BIOTECH INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Wayne Pisano | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Jonathan Rigby | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Angela Holtham | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Parsons James T. | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Kirk Look | ONCY | Stock Option | Award | 260,000 | 260,000 | 01 Jun 2026 | Direct | |||
| Andrew Aromando | ONCY | Stock Option | Award | 260,000 | 260,000 | 01 Jun 2026 | Direct | |||
| Jared Kelly | ONCY | Stock Option | Award | 755,000 | 755,000 | 01 Jun 2026 | Direct | |||
| Patricia S. Andrews | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Bernd R. Seizinger | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Allison Hagerman | ONCY | Stock Option | Award | 260,000 | 260,000 | 01 Jun 2026 | Direct | |||
| Deborah Margaret Brown | ONCY | Stock Option | Award | 30,000 | 30,000 | 01 Jun 2026 | Direct | |||
| Thomas Charles Heineman | ONCY | Stock Option | Award | 260,000 | 260,000 | 01 Jun 2026 | Direct | |||
| John Bearden McAdory | ONCY | Stock Option | Award | 145,000 | 145,000 | 01 Jun 2026 | Direct | |||
| Stephen C. Glover | ONCY | Stock Option | Award | 96,000 | 96,000 | 01 Jun 2026 | Direct | |||
| Jared Kelly | ONCY | Common Shares | Purchase | 4.63% | $4,848 | $0.9600 | 5,050 | 114,050 | 12 Mar 2026 | Direct |
| Parsons James T. | ONCY | Common Shares | Purchase | 31.4% | $10,300 | $1.03 | 10,000 | 41,849 | 11 Mar 2026 | Direct |
| Jared Kelly | ONCY | Common Shares | Purchase | 37.1% | $24,839 | $0.8420 | 29,500 | 109,000 | 12 Feb 2026 | Direct |
| Kirk Look | ONCY | Common Shares | Purchase | 4.36% | $10,104 | $0.8420 | 12,000 | 287,515 | 12 Feb 2026 | Direct |
| Wayne Pisano | ONCY | Common Shares | Purchase | 6.49% | $25,338 | $0.8446 | 30,000 | 492,414 | 12 Feb 2026 | Direct |
| Thomas Charles Heineman | ONCY | Common Shares | Purchase | 4.48% | $10,033 | $0.8270 | 12,132 | 282,818 | 12 Feb 2026 | Direct |
| Deborah Margaret Brown | ONCY | Common Shares | Purchase | 29.5% | $21,240 | $0.8496 | 25,000 | 109,851 | 12 Feb 2026 | Direct |
| Allison Hagerman | ONCY | Common Shares | Purchase | 9.52% | $8,298 | $0.8298 | 10,000 | 115,059 | 12 Feb 2026 | Direct |
| Bernd R. Seizinger | ONCY | Common Shares | Purchase | 7.59% | $33,864 | $0.8466 | 40,000 | 566,991 | 12 Feb 2026 | Direct |
| Patricia S. Andrews | ONCY | Common Shares | Purchase | 82.8% | $30,292 | $0.8557 | 35,400 | 78,128 | 12 Feb 2026 | Direct |
| Jared Kelly | ONCY | Common Shares | Purchase | 7.58% | $4,682 | $0.8360 | 5,600 | 79,500 | 11 Feb 2026 | Direct |
| Bernd R. Seizinger | ONCY | Common Shares | Purchase | 12.8% | $49,590 | $0.8265 | 60,000 | 526,991 | 11 Feb 2026 | Direct |
| Andrew Aromando | ONCY | Common Shares | Purchase | 116.1% | $25,418 | $0.8587 | 29,600 | 55,100 | 11 Feb 2026 | Direct |
| Bernd R. Seizinger | ONCY | Common Shares | Purchase | 27.2% | $103,770 | $1.04 | 100,000 | 466,991 | 16 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.